CareRx (CRRX) Q3 2024 earnings summary

Executive summary

• Achieved fifth consecutive quarter of Adjusted EBITDA growth, driven by operational efficiencies, improved supply terms, and strategic initiatives focused on operational excellence and lean principles.

• Modernized operating platform, reduced net debt, and created a leaner, more efficient platform for future expansion in the seniors care sector.

• Announced and began consolidation of a new state-of-the-art fulfillment center/pharmacy in North Burnaby, BC, to enhance service delivery and operational efficiency.

• Appointed Suzanne Brand as CFO, bringing extensive industry experience and expertise in growth and efficiency.

Financial highlights

• Q3 2024 revenue was $92.8M (CAD 92.8 million), down from $93.8M year-over-year but up from $92.0M sequentially, reflecting a net reduction in beds serviced offset by higher branded pharmaceutical prices.

• Adjusted EBITDA for Q3 2024 was $7.8M, up from $7.3M in Q3 2023 and $7.5M in Q2 2024, with margin rising to 8.4% from 7.8% a year ago.

• Net loss narrowed to $0.4M in Q3 2024 from $1.4M in both Q2 2024 and Q3 2023, mainly due to lower finance costs and cost savings.

• Cash balance at quarter-end was $8.8M, up from $7.2M in Q2; net debt reduced to $38.3M due to higher operating cash flow and loan repayments.

• Cash provided by operations was $12.2M in Q3 2024, up from $8.2M in Q3 2023.

Outlook and guidance

• Double-digit adjusted EBITDA margins targeted for early 2025, following completion of the North Burnaby consolidation.

• Nearly 3,000 new beds secured for onboarding in 2025, with growth expected to accelerate as regulatory approvals are obtained.

• Enhanced operating platform and robust RFP pipeline position the company for sustained profitable growth and sector expansion.